Company Encyclopedia
View More
name
Rhythm Pharma
RYTM.US
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd.
1.946 T
RYTM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking66/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-247.09%E
    • Profit Margin-110.32%E
    • Gross Margin89.28%A
  • Growth ScoreA
    • Revenue YoY54.92%A
    • Net Profit YoY24.41%B
    • Total Assets YoY39.42%A
    • Net Assets YoY93.64%A
  • Cash ScoreB
    • Cash Flow Margin-88.18%D
    • OCF YoY54.92%A
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreC
    • Gearing Ratio41.67%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Rhythm Pharmaceuticals (RYTM): Assessing Valuation as Citigroup Sparks Fresh Optimism with New 'Buy' Rating

    Citigroup's 'Buy' rating on Rhythm Pharmaceuticals (RYTM) has sparked optimism, with shares showing strong gains. Analysts estimate the stock's fair value at $126.31, indicating it's undervalued compared to its recent price of $109.09. Upcoming regulatory approvals and intellectual property extensions are expected to enhance growth opportunities.

    Simplywall·
    US
    RYTM
    +1.02%
    Simplywall·
    US
    RYTM
    +1.02%

    Rhythm Pharmaceuticals Chief Human Resources Officer Pamela J. Cramer Reports Disposal of Common Shares

    Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals Inc., has reported the disposal of common shares of the company. This information was published via the EDGAR system by the U.S. Securities and Exchange Commission.

    Reuters·
    US
    RYTM
    +1.02%
    Reuters·
    US
    RYTM
    +1.02%

    Jefferies Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

    Jefferies analyst Dennis Ding maintained a Buy rating on Rhythm Pharmaceuticals with a $125 price target. Ding, a 4-star analyst, has a 9.3% average return and a 50% success rate. Canaccord Genuity also issued a Buy rating, while TR | OpenAI reiterated a Hold rating. Ding focuses on the Healthcare sector, covering stocks like Mineralys Therapeutics and Amicus.

    Tip Ranks·
    US
    RYTM
    +1.02%
    Tip Ranks·
    US
    RYTM
    +1.02%

    Why Rhythm Pharmaceuticals (RYTM) Is Down After FDA Delays IMCIVREE Review for Rare Obesity Treatment

    Rhythm Pharmaceuticals (RYTM) announced that the FDA has extended the review period for its IMCIVREE treatment for acquired hypothalamic obesity from December 2025 to March 2026, requesting additional trial efficacy data. This delay does not raise new safety concerns but impacts the timeline for regulatory approval. The company reported a revenue increase to $51.3 million but a net loss of $52.9 million, highlighting ongoing financial challenges. Despite the setback, forecasts suggest significant revenue growth by 2028, with varying fair value estimates from the investment community.

    Simplywall·
    US
    RYTM
    +1.02%
    Simplywall·
    US
    RYTM
    +1.02%

    Rhythm Pharmaceuticals Reports Setmelanotide Significantly Reduces BMI in Hypothalamic Obesity Phase 3 Trial

    Rhythm Pharmaceuticals Inc. presented data from the Phase 3 TRANSCEND trial at ObesityWeek® 2025, showing that setmelanotide significantly reduces BMI in patients with acquired hypothalamic obesity. The treatment led to meaningful improvements in cardiometabolic parameters after 52 weeks, with positive feedback from patients and caregivers regarding hunger, weight, energy levels, and physical activity. The results were shared in Atlanta, GA.

    Reuters·
    US
    RYTM
    +1.02%
    Reuters·
    US
    RYTM
    +1.02%
    © 2025 Longbridge｜Disclaimer